FORT SMITH, Ark., Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Endeavor Investor Group (together with its affiliates, “Endeavor” or “we”) today issued the following statement in response to Mawson Infrastructure Group Inc.’s (“Mawson” or the “Company”) announcement that its Board of Directors (the “Board”) has adopted a stockholder rights plan (the “Rights Plan”). Endeavor also expressed its concerns with the Company’s recent dilutive actions that protect the Board and the Company’s management (“Management”) at th ...

Core Viewpoint - Bimini Capital Management, Inc. has amended its Rights Agreement to extend its expiration date and adjust the purchase price, aiming to preserve stockholder value and protect its net operating loss carryforwards [1][2][3]. Group 1: Rights Plan Amendment - The Board of Directors adopted the First Amendment to the existing Rights Agreement, extending the expiration date from December 21, 2025, to December 21, 2030, and increasing the purchase price from $4.76 to $10.20 [1]. - The Rights Plan is intended to safeguard stockholder value and the value of tax assets, specifically net operating loss carryforwards (NOLs), which amounted to approximately $253.9 million as of September 30, 2025 [2]. - The increase in the purchase price is designed to enhance potential dilution for stockholders triggering rights under the plan, thereby reducing the likelihood of an "ownership change" as defined by Section 382 of the Internal Revenue Code [3]. Group 2: Stockholder Approval and Future Actions - The First Amendment will be submitted for stockholder approval at the 2026 annual meeting, with automatic termination of the amendment set for June 30, 2026, if approval is not obtained [4]. - A detailed summary of the First Amendment will be included in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission [5]. Group 3: Company Overview - Bimini Capital Management, Inc. primarily invests in residential mortgage-related securities issued by government-sponsored entities such as Fannie Mae, Freddie Mac, and Ginnie Mae [6]. - The company also manages Orchid Island Capital, Inc., a publicly-traded real estate investment trust, and Royal Palm Capital, LLC, both with similar investment strategies [7][8].

Financial Performance - Net sales increased to $155 million in Q3'25 from $109 million in Q3'24[16] - Adjusted EBITDA rose to $40 million in Q3'25, compared to $17 million in Q3'24[16] - Adjusted EBITDA margin improved to 26% in Q3'25 from 16% in Q3'24[16] - Diluted EPS was $010 in Q3'25, a significant improvement from $(035) in Q3'24[16] Sales and Production - The company saw increased sales volumes of AN (Ammonium Nitrate) and Nitric Acid in Q3'25 compared to Q3'24[8] - UAN (Urea Ammonium Nitrate) sales volumes also increased in Q3'25 compared to Q3'24[8] Market Conditions and Outlook - The company anticipates a strong market outlook for both fertilizer and industrial end markets into 2026[9] - Demand for industrial products is robust, supported by strong gold and copper prices[10, 11] - Strong fertilizer pricing is expected to continue, driven by ammonia supply disruptions and strong demand[13, 15] Balance Sheet and Liquidity - The company's cash and short-term investments totaled $152 million as of September 30, 2025[22] - Total debt was $448 million as of September 30, 2025[22] - Net debt to TTM (Trailing Twelve Months) Adjusted EBITDA was 20X[22]

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to extend its duration by one year to October 30, 2026, in response to significant dislocation in the trading price of its common stock [1][2] Summary by Sections Rights Plan Amendment - The amendment aims to increase potential dilution for any Acquiring Person if the Rights Plan is triggered, allowing stockholders to realize long-term value and reducing the likelihood of control by any person or group without proper compensation [2][4] - The Rights Plan will automatically expire on October 30, 2026, unless redeemed or exchanged earlier by the Company [4] Acquisition and Control - The Board did not adopt the extension in response to a specific takeover threat and retains the ability to engage with parties or accept acquisition proposals if deemed in the best interests of the Company and its stockholders [3] Rights Plan Details - The Rights become exercisable if an Acquiring Person acquires 10% or more of the outstanding common stock (15% for passive institutional investors) [4] - Stockholders above the threshold at the initial announcement are grandfathered but cannot increase ownership without triggering the Rights Plan [4] - Each Right allows the holder to purchase additional shares at $20.00, with a market value of twice the exercise price [4] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines, with a pipeline addressing underserved therapeutic areas [6]

Q2'25 Performance Highlights - Increased total sales volumes by 6% compared with Q2'24, driven by UAN and AN sales[10] - Net sales increased to $151 million in Q2'25 from $140 million in Q2'24[17] - Adjusted EBITDA was $38 million in Q2'25, compared to $42 million in Q2'24[17] - Adjusted EBITDA margin decreased to 25% in Q2'25 from 30% in Q2'24[17] - Diluted EPS was $004 in Q2'25, compared to $013 in Q2'24[17] Balance Sheet and Capital Allocation - Reduced debt by $32 million[10] - Cash and short-term investments were $125 million as of June 30, 2025, compared to $216 million as of June 30, 2024[23] - Total debt was $453 million as of June 30, 2025, compared to $486 million as of June 30, 2024[23] - Net debt to TTM Adjusted EBITDA was 27x[23] El Dorado CCS Project - The El Dorado low carbon ammonia project is progressing towards a 2H'26 startup[10]